Lataa...
Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
Trastuzumab improves outcomes among patients with HER2-positive breast cancer but is associated with a risk of treatment-induced cardiotoxicity (TIC). It is unclear how frequently TIC leads to trastuzumab interruption outside of prospective trials, and how TIC is managed in clinical practice. Patien...
Tallennettuna:
| Julkaisussa: | Breast Cancer Res Treat |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4970316/ https://ncbi.nlm.nih.gov/pubmed/25552363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3253-7 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|